Breast cancer classification algorithm to identify 20 gene signature developed using Microsoft Excel

NewsGuard 100/100 Score

Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training.

Robin Hallett, a graduate student working under the supervision of Dr. John Hassell and other members of his research team from McMaster University, Ontario, Canada, developed the algorithm and used it to identify a 20 gene signature, which performed well on a 151 patient validation dataset. Hallett said, "Until now, constructing such a signature requires the use of various clustering and classification algorithms, which in turn require specialized software and bioinformatics training. Importantly, we completed all steps of our algorithm using Microsoft Excel 2007. This software is widely, if not universally, accessible to the biological research community, suggesting that implementation of this technique will not be hampered by lack of software or training".

The researchers used data from a group of 144 patients to train the algorithm to identify genes whose expression levels correlated with patient survival. The 10 most highly ranked genes predictive of poor prognosis and those 10 genes most highly predictive of good prognosis established a 20-gene expression based predictor, which was found to perform as well as two other models in the validation group. According to Hassell, "Our algorithm produces prediction models with comparable accuracy to other feature selection techniques while having generally better accessibility and useability for biological research scientists. We've begun using our algorithm to generate gene expression based prediction models of breast cancer cell sensitivity to commonly used anti-cancer therapies".

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery